|
시장보고서
상품코드
1890919
이상지질혈증 치료 시장 : 적응증별, 약제 클래스별, 투여 경로별, 연령층별, 성별, 유통경로별, 지역별Lipid Disorder Treatment Market, By Indication, By Drug Class, By Route of Administration, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
이상지질혈증 치료 시장은 2025년에 301억 4,000만 달러로 추정되며, 2032년까지 513억 2,000만 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 7.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 내용 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 301억 4,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 7.90% | 2032년 예측 : | 513억 2,000만 달러 |
이상지질혈증 치료제 세계 시장은 전 세계에서 증가하는 이상지질혈증 및 관련 심혈관계 합병증에 대응하기 위해 제약 및 헬스케어 산업에서 중요한 부문을 차지하고 있습니다. 혈중 콜레스테롤, 중성지방 및 기타 지단백질의 이상 수치를 특징으로 하는 이상지질혈증은 전 세계 수백만 명에게 영향을 미치는 심각한 공중보건 문제로 대두되고 있습니다.
고콜레스테롤혈증, 고중성지방혈증, 혼합형 이상지질혈증 등의 질환은 전 세계에서 주요 사망원인인 심혈관 질환의 주요 위험요인입니다. 치료법에는 스타틴, 피브레이트, 담즙산 흡착제, PCSK9 억제제, 지질 대사의 다른 경로를 표적으로 하는 새로운 혁신적 치료법 등 다양한 치료 접근법이 있습니다.
이 시장은 선진국과 개발도상국의 심혈관 건강에 대한 인식 증가, 비만과 당뇨병 유병률 증가, 좌식 생활습관, 고령화 인구 증가에 의해 주도되고 있습니다. 또한 지속적인 연구개발 활동을 통해 유효성과 안전성이 개선된 혁신적인 치료제를 도입하여 시장 확대에 기여하는 한편, 의료진에게 이상지질혈증을 효과적으로 관리할 수 있는 다양한 치료 옵션을 제공합니다.
시장 역학
세계 이상지질혈증 치료제 시장은 주로 심혈관 및 대사성 질환의 유병률 증가에 의해 주도되고 있으며, 비만, 당뇨병, 고혈압이 세계 이상지질혈증의 주요 요인으로 작용하고 있습니다. 특히 선진국의 고령 인구 증가는 노화에 따른 지질 대사의 변화가 이상지질혈증 발병 위험을 높이기 때문에 시장 성장을 크게 가속화하고 있습니다.
PCSK9 억제제 및 병용요법의 등장과 같은 의약품 개발의 기술적 발전은 치료 패러다임에 혁명을 가져왔고, 난치성 고콜레스테롤혈증 환자들의 치료 옵션을 확대했습니다. 의료비 증가, 진단 능력 향상, 예방적 심혈관 관리에 대한 인식이 높아지면서 시장 확대가 가속화되고 있습니다. 그러나 블록버스터 스타틴 계열 약물의 특허 만료에 따른 제네릭 의약품과의 경쟁과 가격 하락, 신약 승인에 대한 엄격한 규제 요건, 특정 고지혈증 치료제의 장기 안전성 프로파일에 대한 우려 등 시장에는 심각한 제약이 존재합니다.
또한 특히 PCSK9 억제제와 같은 신규 치료제의 높은 치료비는 가격에 민감한 시장에서의 접근성을 제한하고, 상환 문제를 야기하고 있습니다. 이러한 제약에도 불구하고 의료 인프라 개선과 중산층 인구 증가가 수요를 견인하는 개발도상국 미개발 시장에서는 큰 기회가 창출되고 있습니다.
맞춤형 의료 접근법, 바이오마커 기반 치료법, 새로운 약물전달법 개발은 수익성 높은 기회를 제공합니다. 또한 최적의 지질 목표 달성을 위한 병용요법에 대한 관심이 높아지고 희귀 유전성 이상지질혈증에 대한 치료 가능성이 높아짐에 따라 혁신적인 치료 솔루션에 투자하는 제약사들에게 큰 성장 전망을 가져다 줄 것으로 보입니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR%)을 제시함으로써 이상지질혈증 치료 세계 시장에 대한 상세한 분석 정보를 제공합니다.
- 각 부문의 잠재적 매출기회를 확인하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 이상지질혈증 치료제 시장의 주요 기업 개요을 제공합니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 도와줄 것입니다.
- 이 세계 이상지질혈증 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 이상지질혈증 치료제 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 이상지질혈증 치료 시장 : 적응증별, 2020-2032년
- 고콜레스테롤혈증
- 고중성지방혈증
- 혼합형 이상지질혈증
- 죽상동맥경화증성 심혈관 질환(ASCVD)
- 가족성 리포 단백질 리파아제 결핍증
- 기타(유전성 트랜스티레틴 매개 아밀로이드증)
제5장 세계의 이상지질혈증 치료 시장 : 약제 클래스별, 2020-2032년
- 스타틴
- PCSK9 저해제
- 담즙산 흡착제
- 콜레스테롤 흡수 저해제
- 피브라트계 약제
- 나이아신(비타민 B3)
- 오메가 3 지방산
- 병용요법
- 기타 후기 개발 단계약
제6장 세계의 이상지질혈증 치료제 시장 : 유형별, 2020-2032년
- 제네릭
- 브랜드
제7장 세계의 이상지질혈증 치료제 시장 : 투여 경로별, 2020-2032년
- 경구
- 비경구
제8장 세계의 이상지질혈증 치료 시장 : 연령층별, 2020-2032년
- 성인
- 소아
- 고령자
제9장 세계의 이상지질혈증 치료 시장 : 성별, 2020-2032년
- 남성
- 여성
제10장 세계의 이상지질혈증 치료 시장 : 유통경로별, 2020-2032년
- 소매 약국
- 온라인 약국
- 병원 약국
제11장 세계의 이상지질혈증 치료 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck &Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
제13장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Lipid Disorder Treatment Market is estimated to be valued at USD 30.14 Bn in 2025 and is expected to reach USD 51.32 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 30.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.90% | 2032 Value Projection: | USD 51.32 Bn |
The global lipid disorder treatment market represents a critical segment within the pharmaceutical and healthcare industry, addressing the growing prevalence of dyslipidemia and associated cardiovascular complications worldwide. Lipid disorders, characterized by abnormal levels of cholesterol, triglycerides, and other lipoproteins in the blood, have emerged as a significant public health concern affecting millions of individuals globally.
Conditions, including hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia, are primary risk factors for cardiovascular diseases, which remain the leading cause of mortality worldwide. The treatment landscape encompasses various therapeutic approaches, including statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, and emerging novel therapies that target different pathways in lipid metabolism.
The market is driven by increasing awareness of cardiovascular health, rising prevalence of obesity and diabetes, sedentary lifestyles, and aging populations across developed and developing nations. Additionally, continuous research and development activities have led to the introduction of innovative treatment modalities with improved efficacy and safety profiles, contributing to market expansion and providing healthcare professionals with diverse therapeutic options to manage lipid disorders effectively.
Market Dynamics
The global lipid disorder treatment market is primarily driven by the escalating prevalence of cardiovascular diseases and metabolic disorders, with obesity, diabetes, and hypertension serving as key contributing factors to dyslipidemia worldwide. The growing geriatric population, particularly in developed regions, significantly amplifies market growth as age-related lipid metabolism changes increase susceptibility to lipid disorders.
Technological advancements in drug development, including the emergence of PCSK9 inhibitors and combination therapies, have revolutionized treatment paradigms and expanded therapeutic options for patients with refractory hypercholesterolemia. Increasing healthcare expenditure, improved diagnostic capabilities, and rising awareness about preventive cardiovascular care further propel market expansion. However, the market faces substantial restraints including patent expirations of blockbuster statin drugs leading to generic competition and price erosion, stringent regulatory requirements for new drug approvals, and concerns regarding long-term safety profiles of certain lipid-lowering medications.
Additionally, high treatment costs, particularly for novel therapies like PCSK9 inhibitors, limit accessibility in price-sensitive markets and create reimbursement challenges. Despite these constraints, significant opportunities emerge from untapped markets in developing economies where healthcare infrastructure improvements and growing middle-class populations drive demand.
The development of personalized medicine approaches, biomarker-guided therapies, and novel drug delivery systems present lucrative opportunities. Furthermore, increasing focus on combination therapies to achieve optimal lipid targets and the potential for treating rare genetic lipid disorders offer substantial growth prospects for pharmaceutical companies investing in innovative therapeutic solutions.
Key Features of the Study
- This report provides in-depth analysis of the global lipid disorder treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lipid disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen, Sanofi, Regeneron Pharmaceuticals, Novartis, Merck and Co., Pfizer, AstraZeneca, Daiichi Sankyo, Kowa Pharmaceuticals America, Esperion Therapeutics, Amarin Corporation, Chiesi Global Rare Diseases, AbbVie, Viatris, and Teva Pharmaceutical Industries
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lipid disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lipid disorder treatment market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Hypercholesterolemia
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Mixed Dyslipidemia
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Familial Lipoprotein Lipase Deficiency
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Statins
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic
- Brand
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults
- Pediatric
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck & Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Lipid Disorder Treatment Market, By Indication
- Global Lipid Disorder Treatment Market, By Drug Class
- Global Lipid Disorder Treatment Market, By Type
- Global Lipid Disorder Treatment Market, By Route of Administration
- Global Lipid Disorder Treatment Market, By Age Group
- Global Lipid Disorder Treatment Market, By Gender
- Global Lipid Disorder Treatment Market, By Distribution Channel
- Global Lipid Disorder Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Lipid Disorder Treatment Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hypercholesterolemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Dyslipidemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Familial Lipoprotein Lipase Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Lipid Disorder Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lipid Disorder Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lipid Disorder Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lipid Disorder Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lipid Disorder Treatment Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Lipid Disorder Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Lipid Disorder Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals America
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Esperion Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amarin Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiesi Global Rare Diseases
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
